Evidence map›Paper›PMID 20826787›Full record

ArticleThe Journal of biological chemistry2010

Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53.

A R M Ruhul Amin, Dongsheng Wang, Hongzheng Zhang, Shifang Peng, Hyung Ju C Shin, Johann C Brandes, Mourad Tighiouart, Fadlo R Khuri, Zhuo Georgia Chen, Dong M Shin

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A R M Ruhul AminDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Dongsheng Wang
Hongzheng Zhang
Shifang Peng
Hyung Ju C Shin
Johann C Brandes
Mourad Tighiouart
Fadlo R Khuri
Zhuo Georgia Chen
Dong M Shin
Emory University · USQuest Diagnostics (United States) · US

Funding

TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCERP50CA128613 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2007 to 2011
$12.0M
Chemoprevention of the Head and Neck Cancer with ZD1839*U01CA101244 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2004 to 2008
$3.1M
Second Primary Tumor Prevention w/EGFR TKIs & COX-2 inhibitors in H & N CancerR01CA112643 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2006 to 2011
$1.6M
NCI NIH HHS P50 CA128613NCI NIH HHS R01 CA112643NCI NIH HHS U01 CA101244
6 · The paper itself

Abstract

Natural dietary agents have drawn a great deal of attention toward cancer prevention because of their wide safety margin. However, single agent intervention has failed to bring the expected outcome in clinical trials; therefore, combinations of chemopreventive agents are gaining increasingly popularity. In the present study, we investigated a combinatorial approach using two natural dietary polyphenols, luteolin and EGCG, and found that their combination at low doses (at which single agents induce minimal apoptosis) synergistically increased apoptosis (3-5-fold more than the additive level of apoptosis) in both head and neck and lung cancer cell lines. This combination also significantly inhibited growth of xenografted tumors in nude mice. The in vivo findings also were supported by significant inhibition of Ki-67 expression and increase in TUNEL-positive cells in xenografted tissues. Mechanistic studies revealed that the combination induced mitochondria-dependent apoptosis in some cell lines and mitochondria-independent apoptosis in others. Moreover, we found more efficient stabilization and ATM-dependent Ser(15) phosphorylation of p53 due to DNA damage by the combination, and ablation of p53 using shRNA strongly inhibited apoptosis as evidenced by decreased poly(ADP-ribose) polymerase and caspase-3 cleavage. In addition, we observed mitochondrial translocation of p53 after treatment with luteolin or the combination of EGCG and luteolin. Taken together, our results for the first time suggest that the combination of luteolin and EGCG has synergistic/additive growth inhibitory effects and provides an important rationale for future chemoprevention trials of head and neck and lung cancers.

Indexed as

AnimalsAnticarcinogenic AgentsApoptosisAtaxia Telangiectasia Mutated ProteinsCaspase 3CatechinCell Cycle ProteinsCell Line, TumorDNA-Binding ProteinsDNA DamageDrug SynergismGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansKi-67 AntigenLuteolinAnticarcinogenic AgentsAtaxia Telangiectasia Mutated ProteinsATM protein, humanAtm protein, mouseCasp3 protein, mouseCaspase 3CatechinCell Cycle ProteinsDNA-Binding Proteinsepigallocatechin gallateKi-67 AntigenLuteolinProtein Serine-Threonine KinasesTP53 protein, humanTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID20826787
PMCPMC2966071
OpenAlexW2007609428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.